Itβs important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Itβs important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Comparing protein expression in Sf9 and Sf21 insect cells
This case study shows how we used mCherry Red Fluorescent Protein to compare recombinant protein expression in Sf9 versus Sf21 insect cells.
One of the well-established eukaryotic expression systems used at Peak Proteins for expressing secreted, intracellular and membrane proteins is the flashBACTM baculovirus insect cell system (licensed from Oxford Expression Technologies (OET). We routinely use Sf9 and Sf21 cultured insect cells isolated from Spodoptera frugiperda (Fall Armyworm). Different clients often express a preference for one cell line over the other and we wanted a better understanding of which cell host is likely to be preferable. Fluorescent proteins, including the monomeric bright red fluorescent protein mCherry derived from dSRed of Discosoma sea anemones, are a powerful tool for cell biology. We utilised a 6-His tagged mCherry construct to undertake a simple time course in Sf9 and Sf21 cells.
Transfection and Expression of protein in insect cells
Sf9 cells were used to directly generate intracellular mCherry recombinant P0 virus. In this study, either Sf21 cells or Sf9 cells at a point of infection cell density of 2.5x106cells/ml were then infected with this recombinant baculovirus to produce the mCherry red fluorescent protein. Samples were taken at 24 hr, 48 hr, 72 hr and 96 hr post-infection.
Figure 1:Β Uninfected control on the left. Flask infected with mCherry baculovirus on the right.
Protein purification from insect cells using Nickel affinity.
Sf21 cells infected with recombinant 6His tagged mCherry baculovirus were harvested 48 hours post infection. Cells were spun down and protein was purified from the pellet using Nickel-NTA affinity chromatography. ES-MS/MS peptide-mapping confirmed the presence of mCherry.
Figure 1:Β Uninfected control on the left. Flask infected with mCherry baculovirus on the right.
Quantification of recombinant mCherry Protein Expression from Sf9 vs Sf21
Purified mCherry was used to create a calibration curve of known concentrations using a 96-well fluorescence microplate reader. Samples taken from Sf9 and Sf21 cells infected with mCherry baculovirus were read on a fluorescence microplate reader. The calibration curve was used to identify the concentration of intracellular mCherry protein expression in each sample taking into account the cell viability.
Figure 3:Β Graph comparing mCherry expression yields between Sf21 and Sf9 cells over 96 hours.
Conclusion: Sf21 cells expressed protein better than Sf9
There is significantly greater intracellular mCherry protein expression in Sf21 cells compared to Sf9 cells validating why Sf21 cells are our insect cell line of choice for intracellular protein expression. We routinely harvest expression cultures 48 hours post infection with recombinant virus and this study confirms this time-point gives optimum protein expression. Studies with secreted mCherry recombinant virus are now taking place to further investigate optimum cell lines and conditions for secreted proteins in the flashBACTM baculovirus insect cell system. Furthermore, quantification of secreted or intracellular mCherry expression levels are proving to be valuable controls in our mammalian expression systems, highlighting what a powerful tool mCherry protein is in cell biology protein expression studies.